Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N J Tutt

Showing results (1-10 of 51) with videos related to

Pageof 6
Sort By:
Breast Cancer Research : BCR|November 14, 2012
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?Nicholas C Turner, Andrew N J Tutt
Nature|May 6, 2026
Two decades of PARP inhibitor synthetic lethality in cancerChristopher J Lord, Andrew N J Tutt, Alan Ashworth
Cancer Discovery|March 4, 2018
Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast CancerRachael Natrajan, Andrew N J Tutt, Christopher J Lord
Annual Review of Medicine|October 24, 2014
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitorsChristopher J Lord, Andrew N J Tutt, Alan Ashworth
The New England Journal of Medicine|October 6, 2021
Adjuvant Olaparib in BRCA-Mutated Breast Cancer. ReplyAndrew N J Tutt, Judy E Garber, Charles E Geyer
Breast Cancer Research : BCR|August 6, 2014
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersJohnathan A Watkins, Sheeba Irshad, Anita Grigoriadis, et al.
Hematology/Oncology Clinics of North America|November 26, 2022
Systemic Therapy for Hereditary Breast CancersElizabeth J Harvey-Jones, Christopher J Lord, Andrew N J Tutt
EMBO Reports|September 11, 2004
DSS1 is required for RAD51 focus formation and genomic stability in mammalian cellsKatrin Gudmundsdottir, Christopher J Lord, Emily Witt, et al.
Open Biology|July 27, 2022
Opinion: PARP inhibitors in cancer-what do we still need to know?Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt, et al.
EMBO Reports|February 19, 2002
Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiationAndrew N J Tutt, Conny Th M van Oostrom, Gillian M Ross, et al.
Pageof 6

Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Breast Cancer Research : BCR|November 14, 2012
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?Nicholas C Turner, Andrew N J Tutt
Nature|May 6, 2026
Two decades of PARP inhibitor synthetic lethality in cancerChristopher J Lord, Andrew N J Tutt, Alan Ashworth
Cancer Discovery|March 4, 2018
Driver Oncogenes but Not as We Know Them: Targetable Fusion Genes in Breast CancerRachael Natrajan, Andrew N J Tutt, Christopher J Lord
Annual Review of Medicine|October 24, 2014
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitorsChristopher J Lord, Andrew N J Tutt, Alan Ashworth
The New England Journal of Medicine|October 6, 2021
Adjuvant Olaparib in BRCA-Mutated Breast Cancer. ReplyAndrew N J Tutt, Judy E Garber, Charles E Geyer
Breast Cancer Research : BCR|August 6, 2014
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancersJohnathan A Watkins, Sheeba Irshad, Anita Grigoriadis, et al.
Hematology/Oncology Clinics of North America|November 26, 2022
Systemic Therapy for Hereditary Breast CancersElizabeth J Harvey-Jones, Christopher J Lord, Andrew N J Tutt
EMBO Reports|September 11, 2004
DSS1 is required for RAD51 focus formation and genomic stability in mammalian cellsKatrin Gudmundsdottir, Christopher J Lord, Emily Witt, et al.
Open Biology|July 27, 2022
Opinion: PARP inhibitors in cancer-what do we still need to know?Andrew J Wicks, Dragomir B Krastev, Stephen J Pettitt, et al.
EMBO Reports|February 19, 2002
Disruption of Brca2 increases the spontaneous mutation rate in vivo: synergism with ionizing radiationAndrew N J Tutt, Conny Th M van Oostrom, Gillian M Ross, et al.
Pageof 6